Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

UB researchers develop aniontransporters to trigger cancer cell apoptosis

The journal Accounts of Chemical Research, which has a profound impact on Chemistry and other related sciences, publishes on its current issue the article "Anion Transporters and Biological Systems", signed by Professor Ricardo Pérez Tomás, from the Department of Pathology and Experimental Therapy of the Faculty of Medicine at the University of Barcelona, Roberto Quesada, from the Department of Chemistry of the Sciences Faculty at the University of Burgos, and Philip A. Gale, from the University of Southampton, in the United Kingdom.

22 Apr 2013

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC).

22 Apr 2013

GTx to continue two pivotal Phase III clinical trials of enobosarm

GTx, Inc. today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board, resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

16 Apr 2013

New research finds HPV plays role in lung cancer in some patients

A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Male smokers with low levels of serum bilirubin are at higher risk for lung cancer

Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the yellow-tinged chemical are at higher risk for lung cancer and dying from the disease.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells - a specific genetic weakness that can be exploited for new therapies.

4 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer.

2 Apr 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

Small Cell Lung Cancer News and Research

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

UB researchers develop aniontransporters to trigger cancer cell apoptosis

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

GTx to continue two pivotal Phase III clinical trials of enobosarm

New research finds HPV plays role in lung cancer in some patients

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Male smokers with low levels of serum bilirubin are at higher risk for lung cancer

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Neurological researchers study promising new treatment for deadly brain tumors

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News